A New Ebola Vaccine: ExcellGene in a Euro-Swiss Initiative


The repeated Ebola virus outbreaks in West Africa have reached historic proportions and underscore the vulnerability of populations to pathogens. ExcellGene and 12 others are working together to create an effective preventive vaccine.

The Future of Transient Gene Expression

LISBON NOV 14-15 2018

CSO & Founder Prof. Dr. F. Wurm was the keynote speaker in the Optimizing Expression Platforms conference at PEGS Summit Europe in Lisbon, Portugal on the 14-15 November 2018. The topic: Transient Protein (Gene) Expression: From R&D towards Pharmaceutical Manufacturing. The Cambridge Health Institute and Prof. Wurm discussed foreseeable advances in transient protein expression for the next decade.

Expect great science. It's in our DNA.

We are a science-driven CDMO for protein expression services. We provide high-quality CHO and HEK protein from transient & stable expression, upstream & downstream processing services, stable cell line generation, recombinant protein production, cGMP master cell banking and VLP production.

Transient Gene Expression: paper submissions welcome


Transient Gene Expression for Rapid Protein Supply is the topic of an upcoming Special Issue in Processes, an open access journal of chemical and biological process engineering.

Research in this field aims to reduce the cost and time needed to produce proteins of value for academia and industry. In view of this, Dr. Florian Wurm and Dr. Martin Jordan of Merck Biopharma in Switzerland have agreed to be guest editors.

ExcellGene at Bioprocessing Summit Europe

LISBON 20-22 MARCH 2018

Prof. F. Wurm provided a keynote lecture: CHO: Optimizing Cell Culture Technologies for Manufacturing of Recombinant Proteins – Past, Presence and Future at the Bioprocessing Summit Europe conference in Lisbon on March 20th.

Dr. Maria Wurm, CEO of ExcellGene provided a seminar on Bioreactor-Based Optimization and Scale-up Issues for Large Scale Manufacture with Suspension Cultures of Animal Cells, on March 22.

Better media and feeds for high CHO yield


In an article written in November 2017 by Dr. Angelo DePalma in Genetic Engineering and Biotechnology News (GEN), ExcellGene and Prof. F. Wurm were referred to discussing the benefits of better media and feeds as the main driver for the higher yields from CHO cells and the processes developed for large scale manufacturing. This conclusion is based on more than 3 decades of observation and analysis of CHO cells for manufacturing purposes…


From DNA to cell to purified protein product.

We cover the value chain from DNA construction & transfection, to scalable process development for CHO and HEK, to VLP production and rapid protein production for large-scale manufacturing. Our cGMP compliant facility enables the generation of Master Cell Banks (MCB) and Master Working Banks (MWB).

ExcellGene™ technologies are the most advanced for rapid production of recombinant proteins or virus vectors – transient or stable.

Cell Line Development

From DNA to high-yielding clonal population – ready for cGMP banking

Rapid Protein Production

Manufacturing in weeks from 1mL to 100L scale.

Process Development

Fine-tuning of media and process conditions for high yield, parameters for virus or protein.

VLP Production

HEK cell-based production 1ml to 10L,
baculo virus-free.

cGMP Master Cell Banking

300-500 vials


A uniquely science-driven CDMO

Since 2001, ExcellGene has developed proprietary technologies and know-how that are key for the delivery of its clients’ projects on a timely manner and with a high degree of customization.

Some are also available to license.

CHO Transient Transfection Kit

Inhouse protein expression, made easy.

CHOexpress™ host cells

The fastest growing CHO host for biotech.

HEKExpress™ cells

Pioneering single-cell suspension for transient gene expression.

OrbShake bioreactors

Original technology generated by ExcellGene scientists.

Worldwide biotech clients

Our science-based approaches provide some of the fastest and most reliable results in the biotech industry. We have served over a hundred clients, including 6 of the top 10 firms in the biotechnology industry.




Big pharma





  • Biotech 47% 47%
  • Big pharma 25% 25%
  • Academic 10% 10%
  • Other 18% 18%

Ready to kickstart your projects?